The validation of surrogate end points by using data from randomized clinical trials: A case-study in advanced colorectal cancer

Journal of the Royal Statistical Society. Series A: Statistics in Society

Volumn 167, Issue 1, 2004, Pages 103-124

  Burzykowski, Tomasz ^a   Molenberghs, Geert ^a   Buyse, Marc ^b  

^a HASSELT UNIVERSITY   (Belgium)

^b INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

Author keywords

Copula model; Meta analysis; Plackett copula; Surrogate end point; Survival; Tumour response; Two stage model

Indexed keywords

EID: 1542403912     PISSN: 09641998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-985X.2004.00293.x     Document Type: Conference Paper

References (49)

1. Aalen, O. O. (1978) Nonparametric inference for a family of counting processes. Ann. Statist., 6, 701-726.
2. Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10, 896-903.
3. Advanced Colorectal Cancer Meta-Analysis Project (1994) Meta-analysis of randomized trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metatstatic colorectal cancer. J. Clin. Oncol., 12, 960-969.
4. Algina, J. (1999) A comparison of methods for constructing confidence intervals for the squared multiple correlation coefficient. Multiv. Behav. Res., 34, 494-504.
5. Anderson, J. R., Cain, K. C. and Gelber, R. D. (1983) Analysis of survival by tumour response. J. Clin. Oncol., 1, 710-719.
6. Begg, C. B. and Leung, D. H. Y. (2000) On the use of surrogate end points in randomized trials. J. R. Statist. Soc. A, 163, 15-24.
7. Burzykowski, T., Molenberghs, G., Buyse, M., Geys, H. and Renard, D. (2001) Validation of surrogate end points in multiple randomized clinical trials with failure time end points. Appl. Statist., 50, 405-422.
8. Buyse, M. and Molenberghs, G. (1998) The validation of surrogate endpoints in randomized experiments. Biometrics, 54, 1014-1029.
9. Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D. and Geys, H. (2000a) The validation of surrogate end-points in meta-analysis of randomized experiments. Biostatistics, 1, 49-68.
10. Buyse, M. and Piedbois, P. (1996) On the relationship between response to treatment and survival. Statist. Med., 15, 2797-2812.
11. Buyse, M., Thirion, P., Carlson, R. W., Burzykowski, T., Molenberghs, G. and Piedbois, P., for the Meta-Analysis Group in Cancer (2000b) Tumour response to first line chemotherapy improves the survival of patients with advanced colorectal cancer. Lancet, 356, 373-378.
12. Carroll, R. J., Ruppert, D. and Stefanski, L. A. (1995) Measurement Error in Nonlinear Models. London: Chapman and Hall.
13. Chen, T. T., Simon, R. M., Korn, E. L., Anderson, S. J., Lindblad, A. D., Wieand, H. S., Douglass, Jr, H. O., Fisher, B., Hamilton, J. M. and Friedman, M. A. (1998) Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials. Communs Statist. Theory Meth., 27, 1363-1378.
14. Committee for Proprietary Medicinal Products (2001) Note for Guidance on Evaluation of Anticancer Medicinal Products in Man. London: European Agency for the Evaluation of Medicinal Products.
15. Dale, J. R. (1986) Global cross ratio models for bivariate, discrete, ordered responses. Biometrics, 42, 909-917.
16. Daniels, M. J. and Hughes, M. D. (1997) Meta-analysis for the evaluation of potential surrogate markers. Statist. Med., 16, 1965-1982.
17. Dempster, A. P., Laird, N. M. and Rubin, D. B. (1997) Maximum likelihood from incomplete data via the EM algorithm (with discussion). J. R. Statist. Soc. B, 39, 1-38.
18. Ding, C. G. (1996) On the computation of the distribution of the square of the sample multiple correlation coefficient. Comput. Statist. Data Anal., 22, 345-350.
19. Ellenberg, S. S. and Hamilton, J. M. (1989) Surrogate endpoints in clinical trials: cancer. Statist. Med., 8, 405-413.
20. Fisher, R. A. (1928) The general sampling distribution of the multiple correlation coefficient. Proc R. Soc., 121, 654-673.
21. Fleming, T. R. and DeMets, D. L. (1996) Surrogate endpoints in clinical trials: are we being misled? Ann. Intern. Med., 125, 605-613.
22. Fleming, T. R., Prentice, R. L., Pepe, M. S. and Glidden, D. (1994) Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Statist. Med., 13, 955-968.
23. Food and Drug Administration (1996) Reinventing the regulation of cancer drugs - accelerating approval and expanding access. National Performance Review, 1996404883/41014. US Government Printing Office, Washington DC.
24. Fréchet, M. (1951) Sur les tableaux de corrélation dont les marges sont données. Ann. Univ. Lyon A, ser. 3, 14, 53-77.
25. Freedman, L. S., Graubard, B. I. and Schatzkin, A. (1992) Statistical validation of intermediate endpoints for chronic diseases. Statist. Med, 11, 167-178.
26. Fuller, W. A. (1987) Measurement Error Models. New York: Wiley.
27. Gart, J. J. (1966) Alternative analyses of contingency tables, J. R. Statist. Soc. B, 28, 164-179.
28. Genest, C. and McKay, J. (1986) The joy of copulas: bivariate distributions with uniform marginals. Am. Statistn, 40, 280-283.
29. Goldstein, H. (1995) Multilevel Statistical Models, 2nd edn. London: Arnold.
30. van Houwelingen, H. C., Arends, L. R. and Stijnen, T. (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Statist. Med., 21, 589-624.
31. Laird, N. M. and Ware, J. H. (1982) Random-effects models for longitudinal data. Biometrics, 38, 963-974.
32. Mardia, K. V. (1970) Families of Bivariate Distributions. London: Griffin.
33. Meta-Analysis Group in Cancer (1996) Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J. Natn Cancer Inst., 88, 252-258.
34. Meta-Analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of 5-fluorouracil compared with bolus administration in patients with advanced colorectal cancer. J. Clin. Oncol., 16, 301-308.
35. Molenberghs, G., Buyse, M., Geys, H., Renard, D. and Burzykowski, T. (2003) Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Contr. Clin. Trials, 23, 607-625.
36. Molenberghs, G., Geys, H. and Buyse, M. (2001) Evaluation of surrogate endpoints in multiple randomized clinical trials with mixed discrete and continuous outcomes. Statist. Med., 20, 3023-3038.
37. Nelsen, R. G. (1999) An introduction to copulas. Led. Notes Statist., 139.
38. Nelson, W. (1972) Theory and applications of hazard plotting for censored failure data. Technometrics, 14, 945-965.
39. Oakes, D. (1989) Bivariate survival models induced by frailties. J. Am. Statist. Ass., 84, 487-493.
40. Oye, R. and Shapiro, M. F. (1984) Does response make a difference in patient survival? J. Am. Med. Ass., 252, 2722-2725.
41. Plackett, R. L. (1965) A class of bivariate distributions. J. Am. Statist. Ass., 60, 516-522.
42. Prentice, R. L. (1989) Surrogate endpoints in clinical trials: definitions and operational criteria. Statist. Med., 8, 431-440.
43. SAS Institute (1995) SAS/IML Software: Changes and Enhancements through Release 6.11. Cary: SAS Institute.
44. Schafer, J. L. (1997) Analysis of Incomplete Multivariate Data. London: Chapman and Hall.
45. Shih, J. H. and Louis, T. A. (1995) Inferences on association parameter in copula models for bivariate survival data. Biometrics, 51, 1384-1399.
46. Tibaldi, F. S., Certiñas Abrahantes, J., Molenberghs, G., Renard, D., Burzykowski, T., Buyse, M., Parmar, M., Stijnen, T. and Wolfinger, R. (2003) Simplified hierarchical linear models for the evaluation of surrogate end-points. J. Statist. Computn Simuln, 73, 643-658.
47. Verbeke, G. and Molenberghs, G. (2000) Linear Mixed Models for Longitudinal Data. New York: Springer.
48. Wang, W. and Wells, M. T. (2000) Model selection and semiparametric inference for bivariate failure-time data. J. Am. Statist. Ass., 95, 62-76.
49. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO Offset Publication 48. World Health Organization, Geneva.